Questioning Johnson & Johnson's settlement as insufficient for victims

Johnson & Johnson's $5.5bn settlement offer may sound large, but critics say it falls short of what victims deserve given the company's decades-long marketing of a product they allege was tainted with asbestos. The proposal forces every claimant to accept a share of the trust, forgoing the right to sue individually. For those with the most severe illnesses, such as terminal ovarian cancer, the payment could be a fraction of what a jury might award. Prior litigation has seen verdicts of over $2bn in one case—though later reduced—highlighting the potential value of individual claims. Moreover, the bankruptcy strategy allows J&J to avoid public discovery and trials that could reveal internal documents about what the company knew and when. Critics argue this shields J&J from full accountability. The trust also must cover future claims, meaning early claimants may receive less as funds are reserved. Some plaintiffs' attorneys have already urged clients to reject the deal, calling it a corporate maneuver to escape responsibility. Additionally, the settlement does not require J&J to admit wrongdoing or change safety practices. For women who blame J&J for their cancer, the offer may feel like an attempt to minimize financial liability rather than achieve justice. The court will need to decide if the deal is fair, but many victims question whether compensation that is designed to limit the company's total payout can truly compensate for a lifetime of suffering.